#Sweden #AGM #Stockholm #Board of Directors #Sobi

Sobi's Annual General Meeting Highlights

On May 6, 2026, Swedish Orphan Biovitrum AB, commonly known as Sobi, held its Annual General Meeting (AGM) in Stockholm, marking a pivotal moment for the company and its stakeholders. This meeting provided a platform for shareholders to engage and vote on crucial decisions that shape the future of the organization. Below are the key outcomes and resolutions from the AGM that reflect Sobi's commitment to driving growth and innovation in the biopharmaceutical industry.

Financial Approval and Responsibility

The AGM adopted the profit and loss statements along with the balance sheet for the financial year 2025. Shareholders agreed to carry forward the retained earnings, highlighting the company's strong financial management. Moreover, both the Board members and the Chief Executive Officer received a discharge from liability, affirming their stewardship over the company during the stated period.

Election of the Board of Directors

A significant focus of the AGM was the election of the Board of Directors. David Meek was re-elected as Chair of the Board, while Christophe Bourdon, Iris Loew-Friedrich, Staffan Schüberg, and Filippa Stenberg were re-elected as members. Additionally, Mikael Dolsten and Åsa Riisberg were newly elected to join the Board, bringing fresh perspectives and expertise to the leadership team. Collectively, these individuals will guide Sobi through its strategic initiatives and operations until the next AGM.

Remuneration Structures

The AGM also addressed compensation packages for the Board members and auditors, approving the remuneration recommendations put forth by the Nomination Committee. By aligning director remuneration with market standards, Sobi aims to attract and retain top talent.

Long-term Incentive Programs

In an effort to foster employee engagement and contribute to long-term corporate goals, the AGM endorsed several incentive programs. The All Employee Programme, which permits the issuance of up to 223,677 series C shares, was approved. This initiative aims at promoting ownership and commitment among employees and will involve a secondary mechanism to manage associated share transfers through buy-backs.

Similarly, the Management Programme will utilize an equity swap agreement with a third-party to support its execution. Shareholders recognized the importance of these programs in motivating the workforce and ensuring that their interests align with the company’s long-term objectives.

Issuance of New Shares and Bonds

The AGM granted authorization to the Board of Directors to issue new shares, convertible bonds, or warrants, with a cap of 39,710,000 shares. This flexibility will enable Sobi to seize future growth opportunities while managing its capital structure efficiently. Furthermore, to support the incentive programs for 2021-2023, the AGM approved the repurchase of up to 763,064 common shares through the stock exchange.

Conclusion

Sobi's Annual General Meeting not only approved critical financial and structural decisions but also set a clear direction for its future endeavors. As the company continues on its path of innovation and excellence in biopharmaceuticals, the engaged participation of shareholders reflects a collaborative spirit aimed at unlocking the full potential of rare disease treatments. The management and Board are poised to implement these strategies, ensuring a robust growth trajectory and enhanced shareholder value going forward.

For further information regarding the AGM and specific proposals, visit Sobi's official website.